Ataraxis AI is a precision medicine company specializing in developing AI-native diagnostic tests to enhance cancer prognosis and treatment selection. Their flagship product, Ataraxis Breast, is the first clinically validated AI-native prognostic and predictive test for invasive breast cancer. Utilizing multi-modal patient data, including standard pathology slides, this test predicts patient outcomes and aids in personalizing treatment decisions across all breast cancer subtypes. Developed and validated with data from 8,161 patients across 15 institutions in seven countries, Ataraxis Breast has demonstrated superior accuracy compared to standard genomic assays, reducing prediction errors by approximately 50%. The company’s technology leverages AI foundation models, such as Kestrel, trained on hundreds of millions of pathology images to extract predictive morphological features. This approach allows for rapid result delivery within one business day without exhausting physical tissue samples. Ataraxis AI aims to empower physicians with advanced tools to improve treatment selection and patient outcomes. (February 2025)